We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Verzenios

News List

NICE recommends Eli Lilly’s breast cancer drug Verzenios pharmatimes
August 13, 2021
Draft NICE guidance has recommended Eli Lilly’s twice-daily pill Verzenios (abemaciclib) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
NICE rejects Lilly’s Verzenios for advanced breast cancer pharmatimes
February 19, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of advanced breast cancer patients.
Lilly’s Verzenios approved by NICE pharmaphorum
January 21, 2019
NICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the NHS.
NICE rejects Lilly’s breast cancer drug Verzenios pharmatimes
November 01, 2018
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
EU nod for Lilly’s new breast cancer drug pharmatimes
October 11, 2018
Eli Lilly’s CDK 4 and 6 inhibitor Verzenios has been approved in Europe for the treatment of certain metastatic breast cancers.